- Home
- PLUR vs KPTI Comparison
PLUR vs KPTI Comparison
Compare PLUR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- KPTI
- Stock Information
- Founded
- PLUR 2001
- KPTI 2008
- Country
- PLUR Israel
- KPTI United States
- Employees
- PLUR N/A
- KPTI N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- KPTI Health Care
- Exchange
- PLUR Nasdaq
- KPTI Nasdaq
- Market Cap
- PLUR 41.9M
- KPTI 44.5M
- IPO Year
- PLUR N/A
- KPTI 2013
- Fundamental
- Price
- PLUR $4.40
- KPTI $4.39
- Analyst Decision
- PLUR Strong Buy
- KPTI Buy
- Analyst Count
- PLUR 1
- KPTI 6
- Target Price
- PLUR $12.00
- KPTI $48.50
- AVG Volume (30 Days)
- PLUR 11.6K
- KPTI 77.1K
- Earning Date
- PLUR 05-13-2025
- KPTI 08-05-2025
- Dividend Yield
- PLUR N/A
- KPTI N/A
- EPS Growth
- PLUR N/A
- KPTI N/A
- EPS
- PLUR N/A
- KPTI N/A
- Revenue
- PLUR $1,034,000.00
- KPTI $142,126,000.00
- Revenue This Year
- PLUR $472.39
- KPTI $2.34
- Revenue Next Year
- PLUR $254.29
- KPTI $13.81
- P/E Ratio
- PLUR N/A
- KPTI N/A
- Revenue Growth
- PLUR 203.23
- KPTI 1.19
- 52 Week Low
- PLUR $3.33
- KPTI $3.51
- 52 Week High
- PLUR $7.13
- KPTI $17.40
- Technical
- Relative Strength Index (RSI)
- PLUR 44.84
- KPTI 42.39
- Support Level
- PLUR $4.27
- KPTI $4.19
- Resistance Level
- PLUR $4.84
- KPTI $4.77
- Average True Range (ATR)
- PLUR 0.29
- KPTI 0.34
- MACD
- PLUR -0.03
- KPTI 0.03
- Stochastic Oscillator
- PLUR 32.31
- KPTI 43.82
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.